PINK1 positively regulates IL-1β-mediated signaling through Tollip and IRAK1 modulation by Hyun Jung Lee & Kwang Chul Chung
RESEARCH Open Access
PINK1 positively regulates IL-1β-mediated
signaling through Tollip and IRAK1 modulation
Hyun Jung Lee and Kwang Chul Chung*
Abstract
Background: Parkinson disease (PD) is characterized by a slow, progressive degeneration of dopaminergic neurons
in the substantianigra. The cause of neuronal loss in PD is not well understood, but several genetic loci, including
PTEN-induced putative kinase 1 (PINK1), have been linked to early-onset autosomal recessive forms of familial PD.
Neuroinflammation greatly contributes to PD neuronal degeneration and pathogenesis. IL-1 is one of the principal
cytokines that regulates various immune and inflammatory responses via the activation of the transcription factors
NF-κB and activating protein-1. Despite the close relationship between PD and neuroinflammation, the functional
roles of PD-linked genes during inflammatory processes remain poorly understood.
Methods: To explore the functional roles of PINK1 in response to IL-1β stimulation, HEK293 cells, mouse embryonic
fibroblasts derived from PINK1-null (PINK1−/−) and control (PINK1+/+) mice, and 293 IL-1RI cells stably expressing type
1 IL-1 receptor were used. Immunoprecipitation and western blot analysis were performed to detect protein–protein
interaction and protein ubiquitination. To confirm the effect of PINK1 on NF-κB activation, NF-κB-dependent firefly
luciferase reporter assay was conducted.
Results: PINK1 specifically binds two components of the IL-1-mediated signaling cascade, Toll-interacting protein
(Tollip) and IL-1 receptor-associated kinase 1 (IRAK1). The association of PINK1 with Tollip, a negative regulator of
IL-1β signaling, increases upon IL-1β stimulation, which then facilitates the dissociation of Tollip from IRAK1 as well
as the assembly of the IRAK1–TNF receptor-associated factor 6 (TRAF6) complex. PINK1 also enhances Lys63-linked
polyubiquitination of IRAK1, an essential modification of recruitment of NF-κB essential modulator and subsequent
IκB kinase activation, and increases formation of the intermediate signalosome including IRAK1, TRAF6, and
transforming growth factor-β activated kinase 1. Furthermore, PINK1 stimulates IL-1β-induced NF-κB activity via
suppression of Tollip inhibitory action.
Conclusions: These results suggest that PINK1 upregulates IL-1β-mediated signaling through the functional
modulation of Tollip and IRAK1. These results further suggest that PINK1 stimulates the ubiquitination of proximal
molecules and increases signalosome formation in the IL-1β-mediated signaling pathway. The present study
therefore supports the idea of the close relationship between neuroinflammation and PD.
Keywords: IL-1β, Inflammation, Parkinson disease, PTEN-induced putative kinase 1, Toll-interacting protein,
IL-1 receptor-associated kinase 1
Introduction
Parkinson disease (PD) is characterized by progressive
dopaminergic neuron loss in the substantianigra pars
compacta of the midbrain [1]. Although the etiology
of PD remains poorly understood, several genetic loci
have been implicated in the pathogenesis of familial PD.
Among them, the PTEN-induced putative kinase 1
(PINK1) gene encodes a serine/threonine kinase that
phosphorylates substrates such as TNF receptor-
associated protein 1 and thus protects cells from death
induced by various stress signals [2,3]. Neuroinflammatory
processes, including microglial activation, astrogliosis, and
lymphocytic infiltration, significantly contribute to neu-
ronal degeneration by producing deleterious proinflam-
matory molecules [4].
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Toll-like receptors (TLRs) are a family of evolutionar-
ily conserved receptors that recognize pathogen-
associated molecular patterns, causing an inflammatory
response via induction of interleukins and other proin-
flammatory proteins [5]. Toll-interacting protein (Tollip)
is an adaptor protein that acts as an inhibitory factor in
TLR signaling cascades [6-8]. When activated by IL-1 or
lipopolysaccharide stimulation, Tollip associates with the
cytoplasmic TIR domains of IL-1 receptor (IL-1R), as
well as TLR2 and TLR4 [6,7,9]. Tollip also interacts with
IL-1 receptor-associated kinase 1 (IRAK1) and sup-
presses its kinase activity [7]. Therefore, in the absence
of infection, Tollip probably maintains immune cells in a
resting state and terminates IL-1R-induced and TLR-
induced inflammatory pathways via suppression of
IRAK1 activity [7,9]. In this regard, Tollip resembles IL-
1R-associated kinase M, which also acts as a negative
regulator in IL-1β signaling. IL-1R-associated kinase M
associates with IRAK1 by blocking IL-1R-associated kin-
ase 4 recruitment, and thereby inhibits IRAK1 phos-
phorylation and/or activation [10,11].
IRAK1 is an adaptor for the Toll/IL-1R receptor sig-
naling complex. Upon IL-1 stimulation, formation of the
heterodimeric receptor complex creates a scaffold for
the association of MyD88 and Tollip [12-14]. IRAK1 is
then recruited to the active receptor complex. In paral-
lel, IL-1R-associated kinase 4 is recruited to the receptor
complex and may phosphorylate IRAK1, thus initiating
further autophosphorylation of IRAK1. Hyperphosphory-
lated IRAK1 dissociates from the receptor complex,
presumably dimerizes, and binds to TNF receptor-
associated factor 6 (TRAF6). IRAK1 binding to TRAF6
functions together with Ubc13/Uev1A to catalyze Lys63-
polyubiquitination of IRAK1. Active IRAK1 subsequently
causes the dimerization and polyubiquitination of
TRAF6, which activates the downstream component,
transforming growth factor-β activated kinase 1 (TAK1).
TAK1 subsequently phosphorylates several regulatory
kinases in different downstream signaling pathways,
which ultimately leads to the production and release of
multiple cytokines via NF-κB activation [15].
We previously revealed that PINK1 directly binds two
components of IL-1β-mediated downstream signaling,
TRAF6 and TAK1 [16]. In addition, PINK1 overexpres-
sion maintains the ubiquitination and phosphorylation
of these two proteins in 293 IL-1RI cells, consequently
resulting in more potent NF-κB activity [16]. Further-
more, silencing PINK1 expression by RNA interference
or the overexpression of the kinase-defective PINK1 mu-
tant suppresses TRAF6 and TAK1 activity and inhibits
IL-1β-induced NF-κB activation. These results suggest
that PINK1 stimulates the IL-1β response by positively
regulating TRAF6 and TAK1. In the present study, we
aimed to investigate whether PINK1 additionally affects
other upstream molecules in the IL-1β signaling pathway
as well as the formation of the IRAK1, TRAF6, and
TAK1 intermediate signalosome complex. We demon-
strate that PINK1 blocks the inhibitory action of Tollip
upon IL-1β stimulation. In addition, PINK1 positively
regulates IL-1β-mediated NF-κB activation via IRAK1
modulation. These findings provide a novel regulatory




DMEM, FBS, FCS, and the LipofectAMINE PLUS re-
agent were purchased from Invitrogen (Carlsbad, CA,
USA). Protein A-Sepharose was obtained from GE
Healthcare Biosciences (Piscataway, NJ, USA) and anti-
PINK1 antibody was purchased from Abgent (San Diego,
CA, USA). The HA, c-Myc, Tollip, IRAK1, TRAF6,
TAK1, actin, and ubiquitin antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Secondary goat anti-IgG and horseradish peroxidase-
conjugated anti-rabbit and anti-mouse IgGs were pur-
chased from Life Technologies (Grand Island, NY, USA).
Flag antiserum and recombinant human IL-1β were
obtained from Sigma (St Louis, MO, USA). Enhanced
chemiluminescencereagent was purchased from Perkin-
Elmer Life and Analytical Sciences (Waltham, MA,
USA). The Lys63-specific anti-ubiquitin antibody was
obtained from Millipore (Temecula, CA, USA). All other
chemicals used in the study were analytical grade com-
mercial products purchased from Sigma.
DNA constructs
Plasmids encoding Flag-IRAK1, Flag-TAK1 and Flag-
TRAF6 were kindly provided by G Takaesu (Keio Univer-
sity, Tokyo, Japan). The mammalian constructs encoding
HA-tagged Tollip and Myc-tagged wild-type hPINK1
(pBOS-3X-myc-hPINK1-WT) were obtained from K
Nakayama (Kyoto University, Kyoto, Japan) and J Chung
(Seoul National University, Seoul, Korea), respectively.
The plasmid encoding the Myc-tagged kinase-deficient
hPINK1 mutant (multi-point mutations at K219A, D362A,
and D384A, termed pBOS-3X-myc-hPINK1-KD) was gen-
erated using the QuikChangeXL site-directed mutagenesis
kit (Stratagene, La Jolla, CA, USA), according to the man-
ufacturer’s protocol. PCR was performed using the follow-
ing primers (mutated codon is underlined in each primer):
K219A, forward primer 50-CCCTTGGCCATCGCGAT
GATGTGGAAC-30 and reverse primer 50-GTTCCA
CATCATCGCGATGGCCAAGGG-30; D362A, forward
primer 50-ATCGCGCACAGAGCCCTGAAATCCGAC-30
and reverse primer 50-GTCGGATTTCAGGGCTCTGT
GCGCGAT-30; D384A, forward primer 50-CTGGTGA
TCGCAGCTTTTGGCTGCTGC-30 and reverse primer
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50-GCAGCAGCCAAAAGCTGCGATCACCAG-30. The
plasmid encoding V5-TRAF6 was generated by subcloning
TRAF6 from pCMV-Flag-TRAF6 into the pcDNA3.1/
V5-His vector using EcoRI and XhoI sites.
Cell culture and DNA transfection
Mouse embryonic fibroblasts (MEFs) derived from
PINK1-null (PINK1−/−) and control (PINK1+/+) mice
were provided by J Shen (Harvard Medical School, Bos-
ton, MA, USA), and 293 IL-1RI cells stably expressing
type 1 IL-1R were a kind gift from G Takaesu (Keio Uni-
versity). Human embryonic kidney cells (HEK293),
PINK1−/−, and PINK1+/+ MEFs were cultured in DMEM
containing 10% FBS, 100 units/ml penicillin, and 100
μg/ml streptomycin at 37°C in 5% CO2. The 293 IL-1RI
cells were cultured in DMEM containing 10% FCS, 100
units/ml penicillin, and 100 μg/ml streptomycin at 37°C
in 5% CO2. DNA transfection was performed using the
LipofectAMINE PLUS reagent (Invitrogen) according to
the manufacturer’s protocol. The total amount of DNA
transfected for each condition was adjusted using paren-
tal empty vector DNA.
Immunoprecipitation and immunoblot assay
Cells were rinsed twice with ice-cold PBS, harvested in
1% Nonidet P40 lysis buffer (50 mM Tris, pH 7.5, 1%
Nonidet P40, 150 mM NaCl, 10% glycerol, 1 mM
Na3VO4, 1 μg/ml leupeptin, 1 μg/ml aprotinin, 1 mM
ethylene glycol tetraacetic acid, 1 mM ethylene diamine
tetraacetic acid, 10 mM NaF, and 0.2 mM phenylmethyl-
sulfonyl fluoride), and briefly sonicated. Lysates were col-
lected by centrifugation at 13,000 × g for 20 minutes at
4°C. For immunoprecipitation, 1 μg appropriate antibody
was incubated overnight at 4°C with 0.5 to 1 mg cell
extracts prepared in cell lysis buffer. Thirty microliters
of a 1:1 suspension of protein A-sepharose beads were
added and incubated for 2 hours at 4°C with gentle
rotation. Beads were pelleted by centrifugation at
10,000 × g for 30 seconds at 4°C, and washed three
times with 1% Nonidet P40 lysis buffer. Immunocom-
plexes were dissociated by boiling in SDS-PAGE sam-
ple buffer, separated by SDS-PAGE, and transferred to
a nitrocellulose membrane. Membranes were blocked
for 1 hour at room temperature in TBST buffer (20
mM Tris, pH 7.5, 137 mM NaCl, and 0.1% Tween 20)
containing 5% nonfat dry milk, followed by overnight
incubation at 4°C in TBST buffer containing 3% nonfat
dry milk and the appropriate primary antibody. Mem-
branes were washed three times in TBST and then
incubated for 1 hour at room temperature with the
secondary IgG-coupled horseradish peroxidase anti-
body. The membranes were washed three times with
TBST, and the signals were visualized with enhanced
chemiluminescence reagent.
Immunocytochemistry
After transfection, cells were washed twice with ice-cold
PBS (pH 7.4), fixed with 3.7% formaldehyde in PBS for
15 minutes, permeabilized with 0.2% Triton X-100 for
20 minutes, blocked with 1% bovine serum albumin
for 30 minutes, and incubated overnight at 4°C with
the primary antibody. After washing with PBS, cells
were incubated for 2 hours with a FITC-conjugated or
TRITC-conjugated secondary antibody. Where specified,
samples were stained with 40,60-diamidino-2-phenylindole
using the SlowFade Antifade kit (Invitrogen). Fixed cells
were visualized using a LSM-510 META confocal micro-
scope (Carl Zeiss, Gottingen, Germany).
Luciferase reporter assay
PINK1+/+ and PINK1−/− MEF cells were grown for
24 hours in six-well plates at a density of 3 × 105 cells/
well. NF-κB-dependent firefly luciferase reporter plasmids
and the renilla luciferase plasmid were co-transfected
into the cells. Forty-eight hours after transfection, the
cells were harvested in passive lysis buffer (Promega,
Madison, WI, USA) and luciferase assays were per-
formed using the Dual-Luciferase Reporter Assay System
(Promega). Relative luciferase activity was calculated by
dividing firefly luciferase activity by renilla luciferase
activity. Data represent three independent experiments
performed in triplicate.
Statistical analysis
Statistical differences were determined using one-way
analysis of variance with the Tukeypost hoc test. All
values were expressed as mean ± standard deviation.
Results
PINK1 physically interacts with Tollip and IRAK1 in
mammalian cells
To examine the role of PINK1 during inflammation, we
performed a yeast two-hybrid assay with full-length
PINK1 as bait. We screened 5 × 106 human fetal brain
cDNA library clones and identified a number of un-
known, as well as previously reported, PINK1-binding
partners, including parkin [17], TRAF6 [16], Tollip, and
IRAK1 (data not shown). To determine the role of
PINK1 in IL-1β-induced inflammatory signaling, we first
determined whether PINK1 binds Tollip in mammalian
cells using co-immunoprecipitation assays. To examine
whether PINK1 can bind Tollip under normal growth
conditions, HEK293 cells were co-transfected with HA-
tagged Tollip and either Myc-tagged wild-type hPINK1
or its kinase-deficient mutant (hPINK1-KD) alone or in
combination. Cell lysates were immunoprecipitated using
anti-c-Myc IgG, followed by immunoblot analyses with
the HA antibody. Consistent with the previous reports
[18,19], ectopic expression of PINK1 generated two
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bands, as shown in western blot analyses (Figure 1A).
The upper band represents full-length PINK1, whereas
the lower band represents the processed isoform of
PINK1 from mitochondria to cytosol. Compared with
PINK1 mutant, the wild-type band appeared to be upper-
shifted, confirming that wild-type PINK1, but not its
kinase-deficient mutant, is a target of autophosphoryla-
tion. In addition, transiently transfected wild-type PINK1
selectively bound Tollip in HEK293 cells (Figure 1A).
Moreover, the kinase-deficient PINK1 mutant still binds
Tollip, suggesting that PINK1 kinase activity is not ne-
cessary for Tollip binding (Figure 1A). To determine
whether endogenous PINK1 binds endogenous Tollip,
HEK293 cell lysates were immunoprecipitated with anti-
PINK1 IgG, followed by immunoblot analyses with the
Tollip antibody. As shown in Figure 1B, endogenous
PINK1 interacted with endogenous Tollip, whereas no
obvious interaction was observed in control immunocom-
plex samples prepared with preimmune IgG (Figure 1B).
These data suggest that the PINK1/Tollip interaction
is not an artifact of DNA transfection but a specific
interaction in mammalian systems. Moreover, immuno-
cytochemical analyses revealed that endogenous PINK1
co-localizes with endogenous Tollip, predominantly in
the cytoplasmic region of HEK293 cells (Figure 1C).
Together, these results suggest that PINK1 specifically
binds Tollip in mammalian cells.
We next investigated whether PINK1 can also bind
IRAK1 in mammalian cells. HEK293 cells were transi-
ently transfected with Flag-tagged IRAK1 plus either
Myc-tagged wild-type PINK1 (hPINK1-WT) or the
kinase-defective mutant (hPINK1-KD). Anti-Flag
immunocomplexes from these cells were subjected to
western blot analyses using the c-Myc antibody. As
shown in Figure 2A, wild-type and kinase-deficient
PINK1 both bind IRAK1 in HEK293 cells. In addition,
endogenous PINK1 directly associates with endogenous
IRAK1 (Figure 2B). Finally, immunocytochemical analyses
showed that endogenous PINK1 and endogenous IRAK1
co-localize in the cytoplasm of HEK293 cells (Figure 2C).
These experiments thus suggest that PINK1 specifically
binds Tollip and IRAK1 in mammalian cells.
PINK1 facilitates the dissociation of Tollip–IRAK1 complex
Based on reports that Tollip negatively regulates the
IL-1β and TNFα signaling pathways [20], we further
explored the functional consequence of PINK1 on Tollip
activity, focusing on the regulation of IL-1β-mediated
inflammatory signaling. First, we investigated whether
IL-1β treatment changes the PINK1/Tollip interaction
and whether their association is affected by PINK1 kin-
ase activity. For this purpose, we utilized 293 IL-1RI
cells stably expressing type I IL-1β receptor [21], which
consequently show much higher response to IL-1β
stimulation. After co-transfection with HA-Tollip plus
either Myc-hPINK1-WT or Myc-hPINK1-KD, 293 IL-1RI
cells were treated with IL-1β. Immunoblot analyses of
the anti-Myc immunocomplexes with HA antibodies
revealed that IL-1β stimulation enhances the association
between PINK1 and Tollip by ~60% (Figure 3A, B). How-
ever, the increased Tollip binding was not remarkably
changed in the presence of the kinase-defective PINK1
(Figure 3A, B).
Figure 1 PINK1 binds Tollip in HEK293 cells. (A) HEK293 cells were transfected for 48 hours with Myc-tagged PTEN-induced putative kinase 1
(PINK1) and/or HA-tagged Toll-interacting protein (Tollip). Immunoprecipitation (IP) of cell lysates was performed with the c-Myc antibody,
followed by immunoblotting with the HA antibody, as indicated. Expression of the transiently transfected proteins was identified by
immunoblotting with the indicated antibodies. *IgG heavy chain. Actin was used as a loading control. (B) HEK293 cell lysates were
immunoprecipitated with the PINK1 antibody, followed by immunoblotting with the Tollip antibody. As a control, cell lysates were
immunoprecipitated with preimmune IgG. PINK1 and Tollip expression in cell extracts was determined by immunoblotting with each antibody.
(C) HEK293 cells were fixed, permeabilized, and incubated for 24 hours with the PINK1or Tollip antibody. Cells were stained with TRITC-conjugated
or FITC-conjugated secondary antibodies and 40,60-diamidino-2-phenylindole (DAPI). Immunostained cells were examined using confocal
microscopy. Scale bar = 20 μm.
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Although Tollip forms a binary complex with IRAK1
in the absence of ligand, this complex is recruited to IL-
1R upon IL-1β stimulation [6]. IRAK1 is phosphorylated,
leading to its rapid dissociation from Tollip, and causing
IRAK1-induced TRAF6 activation [23]. Based on these
reports, we investigated whether PINK1–Tollip binding
affects the sequential protein interaction between Tollip
and IRAK1. 293 IL-1RI cells were transfected with
Myc-hPINK1, HA-Tollip, or Flag-IRAK1 alone or in
combination and co-immunoprecipitation assays were
performed. As expected, Tollip interacts strongly with
IRAK1 regardless of PINK1 expression. Interestingly,
the addition of PINK1 decreases Tollip binding to IRAK1
under IL-1β stimulation (Figure 4A). These results sug-
gest that the IL-1β stimulation-mediated increased bind-
ing of PINK1 to Tollip (Figure 4A) reduces the affinity
between Tollip and IRAK1, which subsequently dis-
sociates Tollip from IRAK1.
To further examine whether PINK1 diminishes the
binding of endogenous Tollip and IRAK1, we compared
the binding pattern and levels in response to IL-1β
stimulation in PINK1−/− and PINK1+/+ MEFs. After
MEFs were treated with IL-1β, cell lysates were immu-
noprecipitated with the Tollip antibody. Immunoblotting
the complex with the IRAK1 antibody revealed that the
endogenous association between IRAK1 and Tollip occurs
Figure 2 PINK1 physically interacts with IRAK1 in HEK293 cells. (A) HEK293 cells were transfected for 48 hours with Myc-PINK1 and/or Flag-
IRAK1. Cell lysates were immunoprecipitated with the c-Myc antibody, followed by immunoblotting with the Flag antibody. Expression of the
transiently transfected proteins was identified by immunoblotting with the indicated antibodies. *IgG heavy chains. Actin was used as a loading
control. (B) HEK293 cell lysates were immunoprecipitated with the IRAK1 antibody, followed by immunoblotting with the PINK1 antibody. As a
control, cell lysates were immunoprecipitated with preimmune IgG. (C) HEK293 cells were fixed, permeabilized, and incubated for 24 hours with
PINK1 or IRAK1 antibodies. Cells were stained with TRITC-conjugated or FITC-conjugated secondary antibodies and 40,60-diamidino-2-phenylindole
(DAPI). Immunostained cells were examined using confocal microscopy. Scale bar = 20 μm. IRAK1, IL-1 receptor-associated kinase 1; PINK1,
PTEN-induced putative kinase 1.
Figure 3 Association between PINK1 and Tollip increases upon IL-1β stimulation. (A),(B) 293 IL-1RI cells were transfected for 42 hours with
Myc-hPINK1-WT, Myc-hPINK1-KD, or HA-Tollip, alone or in combination, and treated with 10 ng/ml IL-1β for 15 minutes. Cell lysates were
subjected to immunoprecipitation (IP) with anti-Myc antibody, followed by immunoblotting with anti-HA antibody. Total cell lysates were also
analyzed with anti-Myc and anti-HA antibodies. *IgG heavy chains. Actin served as a loading control. (A) The binding intensity ((Tollip bound/
Tollip input)/PINK1 IP) was quantified and normalized to the intensity of IP using Image J software [22]. (B) *P<0.05; n.s., not significant.PINK1,
PTEN-induced putative kinase 1; Tollip, Toll-interacting protein.
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more strongly in PINK1−/− MEFs in the absence of IL-1β
stimulation, whereas it was very weak in PINK1+/+ MEFs
(Figure 4B). In addition, the endogenous Tollip/IRAK1
interaction occurs until 10 minutes after IL-1β stimulation
in PINK1−/− MEFs (Figure 4B). Together, these results
suggest that PINK1 facilitates Tollip dissociation from
IRAK1, which may consequently promote IL-1β-induced
downstream signaling.
PINK1 facilitates Lys63-linked polyubiquitination of IRAK1
Recent studies reveal that IRAK1 undergoes Lys63-
linked ubiquitination following IL-1 stimulation. This
modification is essential for the recruitment of NF-κB
essential modulator and subsequent IκB kinase (IKK) ac-
tivation [24,25]. Given the importance of IRAK1 ubiqui-
tination in IL-1 signaling, we determined whether
PINK1 affects IRAK1 ubiquitination upon IL-1β stimu-
lation by conducting in vivoubiquitination assays. The
293 IL-1RI cells were co-transfected with Flag-IRAK1,
HA-ubiquitin, or Myc-hPINK1, alone or in combin-
ation, and stimulated with IL-1β. Immunoblot analyses
of the Flag immunocomplexes with the HA antibody
demonstrate that PINK1 overexpression increases IRAK1
polyubiquitination (Figure 5A, lane 4) compared with
cells expressing IRAK1 and ubiquitin alone (Figure 5A,
lane 3).
Next, we assessed whether IRAK1 polyubiquitination
depends on PINK1 kinase activity. The 293 IL-1RI cells
were transfected with either Myc-hPINK1-WT or Myc-
hPINK1-KD, along with Flag-tagged IRAK1, and then
treated with IL-1β. Immunoblot analyses of the Flag
immunocomplexes with the ubiquitin antibody revealed
that wild-type PINK1 increases IRAK1 polyubiquitina-
tion by 3.5-fold (Figure 5B), whereas it is not significantly
different in the presence of Myc-hPINK1-KD. These
results suggest that PINK1 positively regulates IRAK1
polyubiquitination independent of its kinase activity.
We next addressed whether PINK1 facilitates Lys63-
linked polyubiquitin conjugation to endogenous IRAK1 in
response to IL-1β because this is required for IKK activa-
tion. PINK1−/− and PINK1+/+ MEFs were stimulated with
IL-1β and cell lysates were immunoprecipitated with the
IRAK1 antibody (Figure 5C). Immunoblot analyses with
the Lys63-specific ubiquitin antibody showed that Lys63-
dependent polyubiquitination of IRAK1 in PINK1−/−
MEFs only slightly increases after 30 minutes of IL-1β
stimulation. In contrast, IRAK1 polyubiquitinationin
PINK1+/+ MEFs significantly increased after 10 minutes of
IL-1β treatment, reaching its maximum after 30 minutes.
These results indicate that PINK1 promotes Lys63-
specific polyubiquitination of IRAK1 in mammalian cells.
PINK1 promotes assembly of IRAK1–TRAF6 complex
Upon dissociation from IL-1R, IRAK1 and TRAF6 form
another multi-protein complex at the plasma membrane
consisting of TAK1, TAB1, and TAB2 [26-28]. These
Figure 4 PINK1 facilitates IRAK1 dissociation from Tollip after IL-1β stimulation. (A) 293 IL-1RI cells were transfected for 42 hours with Myc-
PINK1, HA-Tollip, or Flag-IRAK1, alone or in combination, and treated for 15 minutes with 10 ng/ml IL-1β. Cell lysates were immunoprecipitated
with the HA antibody, followed by immunoblot analyses with the Flag or c-Myc antibodies. The relative binding affinities were quantified –
(IRAK1 bound/IRAK1 input)/Tollip IP or (PINK1 bound/PINK1 input)/Tollip IP – and denoted below the upper panel. Open arrow, increased binding
of PINK1 to Tollip. Actin used as a loading control. (B) PINK1−/− or PINK1+/+mouse embryonic fibroblasts were treated with 50 ng/ml IL-1β for the
indicated times. Cell lysates were immunoprecipitated with the Tollip antibody, and immunoblotted with the IRAK1 antibody. The relative
binding affinities were quantified and denoted below the upper panel. *IgG heavy chains. Actin served as a loading control. IRAK1, IL-1 receptor-
associated kinase 1; PINK1, PTEN-induced putative kinase 1; Tollip, Toll-interacting protein.
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findings led us to investigate whether PINK1 affects for-
mation of the IRAK1-TRAF6 complex after IL-1β stimu-
lation. 293 IL-1RI cells were transiently transfected with
Flag-IRAK1 and V5-TRAF6, alone or together with
Myc-hPINK1, and treated with IL-1β. Immunoblot ana-
lyses of the Flag immunocomplexes with the V5 anti-
body revealed that IRAK1/TRAF6 binding occurs weakly
in the absence of PINK1 (Figure 6A). However, PINK1
overexpression enhances their interaction under normal
growth conditions. Moreover, PINK1 remarkably
increased the IRAK1/TRAF6 interaction upon IL-1β
stimulation (Figure 6A), suggesting that PINK1 facili-
tates IRAK1 dissociation from Tollip, which, in turn,
promotes IRAK1 binding to TRAF6.
To examine whether PINK1 promotes the association
of endogenous IRAK1 and TRAF6, we compared levels
of the IRAK1–TRAF6 complex in response to IL-1β
stimulation in PINK1−/− and PINK1+/+ MEFs. The MEFs
were treated sequentially with the proteasomal inhibitor
MG132 and IL-1β, and cell lysates were immunoprecipi-
tated with the TRAF6 antibody. Immunoblotting with
the IRAK1 antibody confirmed that PINK1 significantly
increases the IRAK1–TRAF6 complex (Figure 6B).
PINK1 enhances formation of the intermediate
signalosome, including IRAK1, TRAF6 and TAK1,
upon IL-1β stimulation
Lys63-linked polyubiquitination of IRAK1 and TRAF6
facilitates recruitment of TAK1 and IKK into the com-
plex [29]. In addition, IL-1β treatment recruits endogen-
ous TAK1 to the TRAF6 complex, a crucial step for
activation of TAK1 catalytic activity, and subsequently
triggers NF-κB and mitogen-activated protein kinase.
Based on these reports, we investigated whether, upon
IL-1β stimulation, PINK1 influences formation of the
intermediate signalosome containing IRAK1, TRAF6,
and TAK1. We used PINK1−/− or PINK1+/+ MEFs to de-
termine the effect of PINK1 on formation of the en-
dogenous signalosome. PINK1−/− and PINK1+/+ MEFs
were stimulated with IL-1β for the indicated times
(Figure 7A), and cell lysates were immunoprecipitated
with the TAK1 antibody. Immunoblot analyses with the
Figure 5 PINK1 increases Lys63-dependent polyubiquitination of IRAK1. (A) HEK293 cells were transfected for 48 hours with HA-ubiquitin,
Flag-IRAK1, or Myc-PINK1, alone or in combination. Cell lysates were immunoprecipitated with the Flag antibody, followed by immunoblotting
with the HA antibody. Expression of transiently transfected proteins was confirmed by immunoblotting with the HA, Flag, or c-Myc antibodies.
*IgG heavy chains.Actin served as a loading control. (B) 293 IL-1RI cells were transfected for 42 hours with Flag-IRAK1 alone or together with
either Myc-tagged wild-type PINK1 (WT) or its kinase-defective mutant (KD), and treated for 15 minutes with 10 ng/ml IL-1β. Cell lysates were
immunoprecipitated with the Flag antibody, followed by immunoblotting with the ubiquitin antibody. (C) PINK1−/− and PINK1+/+mouse
embryonic fibroblasts were treated with 50 ng/ml IL-1β for the indicated times. Cell lysates were immunoprecipitated with the IRAK1 antibody,
and immunoblotted with the Lys63-specific ubiquitin antibody. The relative polyubiquitinated IRAK1 levels were quantified and denoted below
the upper panel:(A), (B) (ubiquitinated IRAK1/IRAK1 input)/IRAK1 IP, or (C) (endogenous ubiquitinated IRAK1/endogenous IRAK1)/endogenous
IRAK1 IP.IRAK1, IL-1 receptor-associated kinase 1; PINK1, PTEN-induced putative kinase 1.
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IRAK1 antibody revealed that PINK1 facilitates forma-
tion of the TRAF6-mediated IRAK1–TAK1 complex
(Figure 7A). In addition, western blotting with the
IRAK1 antibody showed that, in response to IL-1β, there
is a time-dependent increase in the upper IRAK1 bands
in PINK1+/+ MEFs. These slower migrating IRAK1
bands are presumed to result from hyperphosphoryla-
tion and ubiquitin modification [30,31]. To obtain
enhanced levels of the PINK1-induced intermediate sig-
nalosome complex, cells were pretreated with MG132
before IL-1β stimulation (Figure 7B). Suppression of
intracellular proteasomal activity led to an accumulation
of ubiquitinated IRAK1 as well as unmodified IRAK1.
Moreover, both modified and unmodified IRAK1 levels
were enhanced in PINK1+/+MEFs, causing a robust re-
cruitment of the intermediate signalosome. Taken to-
gether, these results indicate that PINK1 promotes
assembly of the IRAK1–TRAF6–TAK1 complex, a cru-
cial step for IKK and NF-κB activation.
PINK1 potentiates NF-κB activity via Tollip suppression in
response to IL-1β
To confirm that PINK1 positively regulates IL-1β-
induced proximal signaling, we examined the effect of
PINK1 on NF-κB activation. PINK1−/− or PINK1+/+
MEFs were transfected with Tollip or PINK1, and sti-
mulated with IL-1β, and the lysates were evaluated for
NF-κB transactivation activity. As predicted, ectopic
Tollip expression inhibits NF-κB activity, compared with
mock-transfected cells. In addition, PINK1 overexpres-
sion into PINK1+/+ MEFs abrogated the inhibitory action
of Tollip and increased NF-κB activity (Figure 8). More-
over, compared with the mock-transfected PINK1−/−
MEFs, Tollip expression significantly inhibited NF-κB
activity but the ectopic expression of PINK1 elevated
NF-κB activity. Taken together, these results indicate
that PINK1 potentiates IL-1β-induced NF-κB activity
through suppression of Tollip activity.
Discussion
Neuroinflammation is thought to contribute to the cas-
cade of events leading to neuronal degeneration in many
neurodegenerative diseases, including PD. These events
comprise microglial activation, astrogliosis, and lympho-
cytic infiltration. Despite intensive research, the relation-
ship between PD-linked genes and neuroinflammatory
signaling cascades is poorly understood. Recently, we
reported that PINK1 participates in the IL-1β-mediated
inflammatory signaling pathway through upregulation of
its downstream molecules, TRAF6 and TAK1 [16].
PINK1 enhances TRAF6 autodimerization and autoubi-
quitination, which are essential for TRAF6 E3 activity
and TAK1 polyubiquitination. Furthermore, PINK1
increases Lys63-dependent polyubiquitination of TAK1
and also directly phosphorylates TAK1 [16]. As a re-
sult, PINK1 potentiates NF-κB activity upon IL-1β
Figure 6 PINK1 facilitates assembly of the IRAK1–TRAF6 complex. (A) 293 IL-1RI cells were transfected for 48 hours with Flag-IRAK1, V5-
TRAF6, or Myc-PINK1, alone or in combination, and treated for 15 minuteswith 10 ng/ml IL-1β. Cells were immunoprecipitated with the Flag
antibody, followed by immunoblotting with the V5 or c-Myc antibodies. (B) PINK1−/− or PINK1+/+mouse embryonic fibroblasts were treated with
50 μM MG132 for 30 minutes followed by 50 ng/ml IL-1β for the indicated times. Cell lysates were immunoprecipitated with the TRAF6 antibody,
and immunoblotted with the IRAK1 antibody. The relative binding affinities were quantified and denoted below the upper panel: (A)(TRAF6
bound/TRAF6 input)/IRAK1 IP,or(B) (endogenous IRAK1 bound/endogenous IRAK1)/endogenous TRAF6 IP. *IgG heavy chains. Actin was used as a
loading control. The binding intensity in (B) was quantified and error bars indicate ± standard deviation in triplicate experiments (C). IRAK1, IL-1
receptor-associated kinase 1; PINK1, PTEN-induced putative kinase 1;R.A., relative amounts; TRAF6, TNF receptor-associated factor 6.
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stimulation. These novel findings suggest that a PD-linked
gene may affect neuroinflammation by directly associating
with and positively regulating key enzymes in IL-1β signal-
ing. In the present study, we further examined whether
PINK1 modulates the initial steps of IL-1β-induced in-
flammatory signaling, focusing on Tollip and IRAK1.
We first demonstrated that PINK1 specifically binds
Tollip. The PINK1/Tollip association increased upon IL-
1β stimulation, which facilitated Tollip dissociation from
IRAK1 as well as assembly of the IRAK1–TRAF6 com-
plex. In addition to functioning as a negative IRAK1
regulator, Tollip modulates IL-1RI signaling cascade in
many ways, including sorting IL-1RI at late endosomes
via formation with Tom1 and clathrin [32-34] and serv-
ing as a component of the IL-1RI sumoylation machin-
ery [35]. Regarding Tollip-mediated IRAK1inhibition,
the region near the Tollip UBA domain binds unpho-
sphorylated IRAK1 in normal growth conditions and
can also be phosphorylated by IRAK1 [7]. Therefore,
once activated on the receptor, IRAK1 phosphorylates
Tollip, which may dissociate Tollip from IRAK1 and the
receptor complex. Taken together, our previous and
present findings demonstrate that PINK1 effectively
modulates several sequential steps of IL-1β signaling
through direct binding to multiple upstream and down-
stream proteins in the IL-1β-mediated signaling pathway
and modulating their interactions. In addition, PINK1
positively influences IL-1β-induced inflammation by dir-
ect phosphorylation of TAK1 [16].
Similar to PINK1, we also reported that the RCAN1-
1S protein, a negative regulator of the phosphatase
calcineurin, binds Tollip and positively modulates IL-
1R-mediated signaling pathways by regulating Tollip–
IRAK1–TRAF6 complex formation [36]. Unlike PINK1,
RCAN1-1S interacts with Tollip and TRAF6 but not
IRAK1, which leads to IRAK1 and TRAF6 dissociation
from Tollip. RCAN1-1S also stimulates IL-1R-mediated
Figure 8 PINK1 potentiates NF-κB activity via Tollip
suppression in response to IL-1β. PINK1−/− and PINK1+/+ mouse
embryo fibroblasts were transfected for 36 hours with the NF-κB-
responsive luciferase reporter and control renilla luciferase reporter
alone or together with HA-Tollip and Myc-hPINK1-WT, as indicated.
After cells were treated for 12 hourswith 50 ng/ml IL-1β, relative
luciferase activity was measured and normalized to renilla activity.
Error bars indicate ± standard deviation in triplicate experiments.
***P<0.001. PINK1, PTEN-induced putative kinase 1.
Figure 7 PINK1 enhances formation of the intermediate signalosome including IRAK1, TRAF6, and TAK1. (A),(B) PINK1−/− or PINK1+/+
mouse embryo fibroblasts were pretreated with 50 μM MG132 for 30 minutes(B) and stimulated with 50 ng/ml IL-1β for the indicated times. Cell
lysates were immunoprecipitated with the transforming growth factor-β activated kinase 1 (TAK1) antibody, followed by immunoblotting with
the IL-1 receptor-associated kinase 1 (IRAK1) antibody. The relative binding affinities ((endogenous IRAK1 bound/endogenous IRAK1)/endogenous
TAK1 IP) of samples were quantified and denoted below the upper panel. The binding intensity in (B) was quantified and error bars indicate ±
standard deviation in triplicate experiments (C). PINK1, PTEN-induced putative kinase 1; R.A., relative amounts.
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signaling pathways, including TAK1 activation, NF-κB
transactivation, and IL-8 production, which are all down-
stream of IL-1R activation [36].
Little is known about the putative PINK1-binding tar-
gets and/or substrates largely because of technical diffi-
culties testing PINK1 kinase activity in vivo. However,
several mitochondrial binding proteins have been identi-
fied, including parkin, Omi/HtrA2, and Rictor [37-39].
Additionally TNF receptor-associated protein 1 is a
PINK1 substrate and is a key component mediating the
cytoprotective actions of PINK1 [40]. Very recently,
PINK1 was shown to phosphorylate Miro, a component
of the primary motor/adaptor complex that anchors
kinesin to the mitochondrial surface [41]. Moreover, we
recently demonstrated that PINK1 directly phosphory-
lates TAK1, whereas it binds to TRAF6 and TAK1 [16].
In the present work, we found that PINK1 binds to
Tollip and IRAK1, but their functional alterations are
not via direct phosphorylation because wild-type and
kinase-defective PINK1 influence them to a similar
extent. PINK1’s mechanism of action is analogous to the
well-characterized extracellular signal-regulated kinase 2
(ERK2) that activates poly(ADP-ribose) polymerase 1,
topoisomerase II, and MKP-1 by direct protein inter-
action, independent of its kinase function [42]. In
addition, ERK1 and ERK2 regulate cell cycle entry by dis-
rupting the retinoblastoma pocket protein and laminA
interaction in a kinase-independent fashion [42].
Increasing evidence indicates that PINK1 is localized
in both the mitochondria and cytosol [18,19,43,44].
These reports suggest PINK1 has a dual localization and
possibly two different functions, depending on its cellu-
lar localization [44,45]. In the cytoplasm, PINK1 forms a
complex with parkin and DJ-1, which promotes the ubi-
quitination and degradation of parkin substrates in
neuroblastoma cells [46]. Furthermore, PINK1 exerts its
cytoprotective function in the mitochondria as well as
in the cytoplasm through activation of mTORC2 and
Akt [40]. In addition, our recent findings [16] and the
current study suggest that an additional role for PINK1
in the cytoplasm is regulation of IL-1β-mediated up-
stream signaling via modulation of multiple targets.
We additionally demonstrated that PINK1 activates
IRAK1 and facilitates assembly of the IRAK1–TRAF6
complex upon IL-1β stimulation. IRAK1 appears to play
a crucial role in facilitating the multi-protein signaling
complex or signalosome. IRAK1 links the active receptor
complex to the central adaptor and co-activator protein
TRAF6. Thus, IRAK1 may be a switch molecule that
turns on signalosome formation (mediated through
TRAF6 dimerization and TAB2 recruitment) [47]. Spe-
cifically, activation of the TLR/IL-1R signaling cascade
induces rapid IRAK1 autophosphorylation, transient
IRAK1 activation with the appearance of higher molecular
weight forms, and the loss of IRAK1 protein [30]. Decrea-
sed IRAK1 levels correlate with the covalent attachment
of Lys48-linked polyubiquitin and the targeting of IRAK1
for proteasomal degradation. TRAF6 and Pellino par-
ticipate in Lys63-linked polyubiquitination of IRAK1
[24,47,49], which consequently recruits NF-κB essential
modulator for subsequent NF-κB activation [24,25]. In
fact, Tollip overexpression dramatically inhibits IRAK1
kinase activity [7] and suppresses NF-κB activation [6,7,9].
We observed the polyubiquitination of endogenous
IRAK1 increases in PINK1+/+ MEFs, compared with
PINK1−/− cells. Furthermore, the IRAK1 protein level is
enhanced in PINK1+/+ MEFs. These data suggest that
PINK1 stimulates Lys63-linked polyubiquitination of
IRAK1, but delays Lys48-linked polyubiquitination of
IRAK1 and proteasomal degradation. In this manner,
upon IL-1β stimulation, PINK1 may facilitate signalo-
some formation containing IRAK1, TRAF6, and TAK1.
These data were further supported by the finding that
Tollip overexpression impairs NF-κB activation, which is
rescued by co-expression of wild-type PINK1.
Several molecules mediate IRAK1 ubiquitination, in-
cluding TRAF6 and Pellino. For example, TRAF6 func-
tions as an E3 ubiquitin ligase, together with Ubc13/
Uev1A, which conjugates Lys63-linked polyubiquitin
chains to itself as well as IRAK1 and subsequently
recruits and activates IKK [24]. The three mammalian
Pellino proteins possess C-terminal RING-like domains
that catalyze IRAK polyubiquitination. Pellino proteins
are phosphorylated by IRAK1 and IL-1R-associated kin-
ase 4, which enhances Pellino E3 ligase activity [48]. Fur-
thermore, IRAK1 kinase activity promotes the Pellino
protein degradation and this might be an important
regulatory mechanism that controls TLR signaling. A re-
cent report proposed that Pellino3 negatively regulates
TAK1-mediated activation of NF-κB, with inhibitory
effects dependent on Pellino3-mediated Lys63-linked
polyubiquitination of IRAK1 [49]. The authors pro-
pose that, upon IL-1β stimulation, Pellino3-mediated
Lys63-linked IRAK polyubiquitination competes with
Lys48-linked IRAK polyubiquitination for the same
ubiquitination site, Lys134 of IRAK. Pellino3 therefore
blocks IRAK degradation and thus inhibits IL-1-
induced NF-κB activation.
PINK1 also stimulates signalosome complex forma-
tion, involving IRAK1, TRAF6, and TAK1. In addition,
IL-1R-associated kinase 4 binds and phosphorylates
IRAK1 at Thr209, Thr387, and Ser376 residues, which
triggers IRAK1 autophosphorylation within the N-
terminal ProST region, its dissociation from MyD88,
and subsequent formation of an intermediary signalo-
some complex at the plasma membrane [21,25,28,50].
Taken together, the results of the present study suggest
that PD-linked PINK1 positively regulates the early events
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of IL-1β-induced signaling. These findings further imply
that PINK1 can contribute to PD pathogenesis by affec-
ting the accompanying inflammatory response.
Conclusions
While inflammation largely contributes to the pathogen-
esis of PD, the functional link between PINK1 and PD-
linked neuroinflammation remains poorly understood.
We previously revealed that PINK1 stimulates the IL-1β
response by positively regulating two components of IL-
1β-mediated downstream signaling, TRAF6 and TAK1.
In the present study, we investigated whether PINK1
additionally affects other upstream molecules in the
IL-1β signaling pathway as well as the formation of
the intermediate signalosome complex. Here we show
that PINK1 stimulates IL-1β-induced signaling via sup-
pression of Tollip inhibitory action, potentiation of Lys63-
linked IRAK1 ubiquitination, and facilitation of an
intermediate signalosome complex formation containing
IRAK1, TRAF6, and TAK1. These results suggest that
PINK1 effectively modulates several sequential steps of
IL-1β signaling through direct binding to multiple up-
stream and downstream proteins in IL-1β-mediated sig-
naling pathway and modulating their interactions. The
present studytherefore additionally suggests that PINK1
may contribute to the pathogenesis of PD by affecting
the accompanying inflammatory response.
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